RELATED CONTENT
NEWS
- 2011 US submission for Genentech/Curis' vismodegib in basal cell carcinoma
- NICE issues final positive guidance for GSK's Votrient
- NICE to review Fabre's Javlor again as comparison with unlicensed drugs deemed unfair
- Panel urges FDA to reject Novartis gouty arthritis drug on safety concerns


